Financial Contrast: CERo Therapeutics (NASDAQ:CERO) and ImmunityBio (NASDAQ:IBRX)

ImmunityBio (NASDAQ:IBRX) and CERo Therapeutics (NASDAQ:CERO) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Earnings & Valuation

This table compares ImmunityBio and CERo Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$1.31 million	2,822.34	-$583.20 million	($0.97)	-5.46
CERo Therapeutics	N/A	N/A	-$2.54 million	N/A	N/A

CERo Therapeutics has lower revenue, but higher earnings than ImmunityBio.

Profitability

This table compares ImmunityBio and CERo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-45,691.66%	N/A	-108.04%
CERo Therapeutics	N/A	N/A	-67.60%

Analyst Ratings

This is a breakdown of current recommendations for ImmunityBio and CERo Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	0	1	0	1	3.00
CERo Therapeutics	0	0	0	0	0.00

ImmunityBio currently has a consensus target price of $4.75, indicating a potential downside of 10.38%. Given ImmunityBio’s stronger consensus rating and higher probable upside, research analysts clearly believe ImmunityBio is more favorable than CERo Therapeutics.

Risk and Volatility

ImmunityBio has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of -0.5, indicating that its share price is 150% less volatile than the S&P 500.

Institutional & Insider Ownership

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are held by institutional investors. 83.4% of ImmunityBio shares are held by company insiders. Comparatively, 18.0% of CERo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

ImmunityBio beats CERo Therapeutics on 6 of the 10 factors compared between the two stocks.

About ImmunityBio

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.